United States Patent 9,161,920: Claim Scope, Vimovo Patent Estate, Generic Entry and Litigation Risk

US Patent 9,161,920 covers a method of reducing NSAID-associated gastric ulcers by administering a tablet that combines naproxen with esomeprazole in a pH-dependent, coordinated-release design. The broadest claims require both a clinical-use element and a specific dosage-form architecture.

The patent is directed to the naproxen/esomeprazole product commercialized as Vimovo. Its principal technical distinction is that esomeprazole is released in the stomach, while naproxen remains substantially protected until the dosage form reaches a medium with a pH of at least 3.5. The claims do not cover ordinary co-administration of separate naproxen and esomeprazole products.

The patent estate is historically important but presents limited current blocking value if its statutory term has expired or if later-listed formulation patents do not remain enforceable. Generic competition is governed by the full Orange Book estate, not by Patent 9,161,920 alone.

What drug and product does US Patent 9,161,920 protect?

US Patent 9,161,920 protects the therapeutic use of a fixed-dose naproxen/esomeprazole tablet corresponding to Vimovo, marketed in strengths including 500 mg naproxen/20 mg esomeprazole and 375 mg naproxen/20 mg esomeprazole.

The product is designed to address two pharmacologic problems:

Naproxen provides analgesic and anti-inflammatory activity.
Esomeprazole suppresses gastric acid and is intended to reduce NSAID-associated gastric ulcer risk.

The patent requires a coordinated release profile:

Component	Claimed requirement
Naproxen	200 to 600 mg per unit dose in claim 1; 200 to 600 mg in claim 12
Esomeprazole	5 to 100 mg per unit dose in claim 1; 5 to 100 mg in claim 13
Dosage form	Tablet
Clinical use	Chronic NSAID treatment in a patient at risk of NSAID-associated ulcer
Esomeprazole release	At least part released regardless of medium pH
Naproxen release	At least part inhibited unless the medium has a pH of 3.5 or higher
Core architecture	Naproxen core with a coating that inhibits release below pH 3.5
Outer layer	Esomeprazole layer, including a non-enteric film coating that releases in the stomach

The commercial product’s architecture generally uses an immediate-release esomeprazole layer surrounding or positioned outside an enteric-coated naproxen core. The claims are drafted around that functional architecture rather than around a particular excipient, manufacturing machine, or brand name.

What are the independent claims in US Patent 9,161,920?

Claims 1 and 11 are the two independent claims.

Claim 1: broad functional combination claim

Claim 1 requires a method of reducing the incidence of NSAID-associated gastric ulcers by administering a tablet containing:

naproxen at 200 to 600 mg;
esomeprazole at 5 to 100 mg;
an esomeprazole portion that releases regardless of pH; and
a naproxen portion whose release is inhibited unless the medium reaches pH 3.5 or higher.

Claim 1 is broader than claim 11 because it does not expressly require a naproxen core layer and a separate esomeprazole layer. It can potentially reach different tablet arrangements if they satisfy the claimed release behavior.

The claim has four material limitations:

A patient population requiring chronic NSAID therapy.
Risk of developing an NSAID-associated ulcer.
A therapeutic objective of reducing ulcer incidence.
A composition with defined naproxen, esomeprazole and pH-dependent release characteristics.

Claim 11: structural tablet claim

Claim 11 narrows the architecture. It requires:

a core layer containing naproxen;
a coating that prevents naproxen release unless the medium has a pH of at least 3.5;
a layer containing esomeprazole; and
a non-enteric film coating on that esomeprazole layer that releases the esomeprazole in the stomach.

Claim 11 is more closely aligned with the commercial multilayer tablet design. A competing product that uses the same core-and-outer-layer architecture faces greater literal infringement risk than a product using a materially different physical arrangement.

How do the dependent claims narrow the patent scope?

Claims 2 through 10 depend from claim 1. Claims 12 through 15 depend from claim 11.

Claims	Added limitation	Practical effect
2	Naproxen in a core with a pH-dependent coating	Requires a coated naproxen core
3	Multilayer tablet with a core and outer layers	Excludes many simple single-layer designs
4	Core contains naproxen	Links the core to the active NSAID
5	At least one outer layer contains esomeprazole	Requires external positioning of esomeprazole
6	Outer layers do not contain naproxen	Separates naproxen from the outer layer
7	At least one carrier	Low-value narrowing limitation because pharmaceutical carriers are common
8	Specific auxiliary agents	Covers conventional excipients and processing aids
9	Ingredient to adjust pH	Covers pH-modifying excipients
10	Osteoarthritis or rheumatoid arthritis	Narrows the indication
12	Naproxen at 200 to 600 mg	Dose-limited version of claim 11
13	Esomeprazole at 5 to 100 mg	Dose-limited version of claim 11
14	Both specified dose ranges	Closely tracks claim 1’s dose combination
15	Osteoarthritis or rheumatoid arthritis	Disease-specific version of claim 11

Claims 7 through 9 add conventional formulation elements. They may provide fallback positions during prosecution or litigation, but they are unlikely to create a strong independent barrier against a product that already practices the more important core-release limitations.

Claims 10 and 15 are method-of-use claims limited to osteoarthritis or rheumatoid arthritis. Their commercial value depends on the labeling and marketing of a competing product. They are less useful against a generic whose FDA-approved labeling closely follows Vimovo’s chronic NSAID indication.

What formulations are protected by US Patent 9,161,920?

The patent principally protects a multilayer or functionally equivalent tablet with differentiated release zones.

Protected formulation characteristics

A formulation is within the technical center of the patent when it has:

naproxen in a central or internal layer;
an enteric or pH-dependent barrier around the naproxen;
esomeprazole outside the naproxen barrier;
immediate or early gastric release of esomeprazole; and
delayed naproxen release until exposure to a pH of at least 3.5.

The claim language is functional. A competing formulation does not necessarily avoid infringement merely by changing the polymer, coating thickness, excipient, tablet shape or manufacturing process.

Formulations that may present design-around opportunities

Potentially lower-risk designs include:

separate tablets administered together rather than a single tablet;
a single tablet in which naproxen and esomeprazole are not arranged in a core-and-layer structure;
a formulation using a different acid-resistant threshold;
a product in which esomeprazole is not released in the stomach;
a formulation that releases both active ingredients in a materially different sequence;
a product with naproxen outside the pH-dependent barrier rather than inside it.

These design-around theories remain fact dependent. The patent includes both structural and functional language, and an equivalent-release argument could be asserted even where the physical coating differs.

How strong is the patent estate for Vimovo?

The estate is technically coherent because its claims cover the product’s central value proposition: combining NSAID therapy with gastric protection in one tablet while separating the release environments.

Its strength varies by claim category.

Claim category	Relative strength	Reason
Core naproxen with pH-dependent coating	High	Closely tracks the product’s central formulation
Immediate-release esomeprazole outer layer	High	Distinguishes the product from conventional enteric PPI designs
Broad method claim 1	Moderate	Covers functional alternatives but requires proof of release behavior and clinical-use facts
Dose ranges	Moderate	Useful against products matching commercial strengths
Excipients and carriers	Low to moderate	Conventional ingredients create limited differentiation
Osteoarthritis and rheumatoid arthritis limitations	Moderate	Stronger where labeling expressly identifies those indications
Manufacturing-process protection	Limited in these claims	The quoted claims do not require a particular process

The best litigation claims are typically claims 1, 2, 3, 5, 11, 12, 13 and 14. Claims 7 through 9 are more likely to operate as dependent fallback claims than as primary enforcement tools.

What is the Orange Book status of US Patent 9,161,920?

The relevant reference product is Vimovo, NDA 022511. Vimovo was approved by the FDA as a delayed-release tablet containing naproxen and esomeprazole magnesium. FDA Orange Book listings for the product have included patents directed to the combination product, its formulation and its method of use.[1]

Orange Book relevance depends on three separate questions:

Whether Patent 9,161,920 was listed for the applicable NDA and strength.
Whether the patent’s term remained unexpired when an ANDA was filed.
Whether the patent was still enforceable after any terminal disclaimer, patent-term adjustment, pediatric extension or statutory disclaimer.

A listed patent can trigger a Paragraph IV notice and an infringement action. Listing alone does not establish validity or infringement. The Orange Book records the NDA sponsor’s patent certification framework; it does not adjudicate the patent’s scope.

The patent’s practical blocking value should therefore be analyzed against:

the listing history for NDA 022511;
the current FDA patent and exclusivity data;
any terminal disclaimer;
any patent-term adjustment;
the filing date of the relevant ANDA; and
any settlement or judgment affecting launch.

When does US Patent 9,161,920 lose exclusivity?

The patent’s enforceable term is determined under 35 U.S.C. § 154, generally 20 years from the earliest effective nonprovisional filing date for the relevant family, subject to patent-term adjustment, terminal disclaimers and other statutory rules.[2]

The grant date, October 20, 2015, does not determine expiration. A continuation patent normally cannot extend the family beyond the applicable 20-year term, although patent-term adjustment can alter the final date.

The public patent record should be used to confirm:

earliest priority and nonprovisional filing dates;
patent-term adjustment;
terminal-disclaimer status;
reexamination or post-grant proceedings;
maintenance-fee status; and
any patent-term extension.

For commercial planning, the key distinction is between regulatory exclusivity and patent exclusivity. FDA approval of Vimovo and any three-year new-clinical-investigation exclusivity are separate from the patent term. Once all blocking patents expire or are removed from the relevant Orange Book record, an ANDA applicant can obtain approval if it satisfies the remaining regulatory requirements.

Which companies have challenged Vimovo patent protection?

Generic-drug challenges to Vimovo have centered on ANDA filings directed to the naproxen/esomeprazole delayed-release combination. Typical challenges use one or more of the following positions:

the claims are anticipated by earlier naproxen/PPI combination disclosures;
the claimed release profile would have been obvious;
the patent lacks adequate written description or enablement across the full dose and formulation ranges;
the proposed generic does not practice the claimed multilayer structure;
the proposed generic does not meet the pH 3.5 release limitation; or
method-of-use claims are not infringed because the ANDA labeling omits the patented indication.

Publicly reported litigation and settlement information has involved generic manufacturers seeking approval for naproxen/esomeprazole products, including Dr. Reddy’s Laboratories and other ANDA applicants. The legal effect of each challenge depends on the patent claims asserted, the ANDA formulation, the Paragraph IV notice and the settlement terms.

A Paragraph IV certification is not a final invalidity determination. A sponsor’s failure to sue within the statutory period can affect the 30-month stay, but it does not automatically invalidate the patent.

What patent litigation affects US Patent 9,161,920?

The key litigation event in an ANDA case is usually the filing of an infringement complaint within 45 days after receipt of a Paragraph IV notice. That filing can trigger a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions and court action.[3]

Relevant litigation questions include:

Issue	Business significance
Patent listed in the Orange Book	Determines whether a Paragraph IV certification is available
Paragraph IV notice	Starts the patent dispute process
45-day complaint period	Controls whether the automatic stay may apply
30-month stay	Delays ANDA approval, not necessarily commercial launch
Claim construction	Defines “inhibited,” “regardless of pH,” “core layer” and “non-enteric film coating”
ANDA formulation	Determines literal infringement risk
Induced infringement	Depends on proposed labeling and promotion
Settlement terms	May establish an agreed launch date or license
Court judgment	Determines enforceability against the particular generic

The most important claim-construction disputes would likely concern the release limitations. “Inhibited unless” does not necessarily mean complete prevention of release. “Regardless of the pH” may require a defined level of pH-independent release rather than absolute release at every pH. Those terms would be evaluated against the specification, prosecution history and expert dissolution evidence.

What generic launch risks exist for naproxen/esomeprazole?

Generic entry can occur through several scenarios.

Scenario 1: Launch after patent expiry

This is the lowest litigation-risk scenario. The generic applicant waits until all relevant Orange Book patents expire or become otherwise nonblocking.

Scenario 2: Paragraph IV launch after litigation

A generic may launch at risk after receiving a favorable court decision, a dismissal, expiration of the stay, or a settlement that permits entry. The manufacturer faces damages and injunctive risk if the patent is later upheld.

Scenario 3: Design-around launch

A generic may use a different tablet structure or release profile. The principal technical risk is that dissolution testing or the doctrine of equivalents brings the product within claims 1 or 11.

Scenario 4: Label-based carve-out

A generic may attempt to omit the patented osteoarthritis or rheumatoid arthritis use. This strategy is less effective if the remaining labeling still instructs chronic NSAID use in patients at risk of NSAID-associated ulcers.

Scenario 5: Authorized generic or licensed entry

The brand owner or its licensee may supply an authorized generic or license a generic manufacturer. This can materially change the commercial impact of ANDA approval without eliminating the underlying patent dispute.

What licensing deals affect the patent landscape?

The commercial history of Vimovo includes a development and commercialization relationship between Pozen and AstraZeneca. Pozen developed the naproxen/esomeprazole combination, while AstraZeneca commercialized Vimovo in multiple markets. AstraZeneca later transferred or licensed certain commercial rights as its portfolio strategy changed. Horizon Pharma became associated with Vimovo commercialization in the United States, and Amgen acquired Horizon in 2023.[4][5]

These transactions matter because patent ownership, NDA sponsorship, marketing rights and litigation authority may not reside in the same entity. A transaction may transfer:

US commercialization rights;
patent prosecution rights;
Orange Book listing authority;
rights to sue ANDA applicants;
settlement authority; or
rights outside the United States.

The operating party at any particular time must be confirmed from assignment records, SEC filings, FDA records and the applicable transaction documents.

How does US Patent 9,161,920 compare with competing patent protections?

Protection type	Patent 9,161,920	Competing protection
Active ingredients	Naproxen plus esomeprazole	May cover naproxen, a PPI or another gastroprotective agent
Product format	Tablet, including multilayer architecture	Separate capsules, tablets or different combination formats
Release profile	Esomeprazole releases independently of pH; naproxen delayed until pH 3.5	Alternative enteric thresholds or simultaneous release
Clinical use	NSAID-associated ulcer reduction	Pain treatment, acid suppression or other indications
Formulation detail	Core, coating and outer esomeprazole layer	Polymer-specific, process-specific or particle-specific patents
Regulatory relevance	Potential Orange Book method and formulation listing	May be nonlisted process or manufacturing patents
Biosimilar risk	None in the biologic sense	Vimovo is a small-molecule product; ANDA, not biosimilar, is the relevant pathway

Biosimilar risk is not applicable to Vimovo. Naproxen and esomeprazole are small-molecule active ingredients, so competitors use the ANDA pathway under section 505(j), not the biosimilar pathway under section 351(k).

What manufacturing and IP barriers remain?

The principal manufacturing barrier is not the chemical synthesis of naproxen or esomeprazole. Both active ingredients are established small molecules with multiple suppliers. The barrier is reproducible manufacture of a tablet that meets:

layer-to-layer content uniformity;
esomeprazole stability;
protection from acidic degradation;
defined naproxen dissolution behavior;
pH-triggered release at or above 3.5;
mechanical integrity during compression and coating; and
FDA comparative dissolution requirements.

The formulation may require separate processing of the naproxen core, the enteric coating and the esomeprazole-containing outer layer. Scale-up can create risks involving coating defects, acid migration, moisture exposure and dissolution variability.

Those manufacturing difficulties can support commercial differentiation, but they do not independently extend patent exclusivity. A company needs a valid, enforceable patent claim or regulatory barrier to prevent lawful generic competition.

What is the geographic coverage of the patent?

US Patent 9,161,920 has territorial effect only in the United States. It does not block sale, manufacture or use in Canada, Europe, Japan or other jurisdictions.

International protection would depend on corresponding national patents. The relevant foreign family members may differ in:

claim scope;
prosecution history;
expiration date;
validity outcome;
Orange Book-equivalent listing;
SPC or patent-term-extension status; and
litigation history.

A US ANDA settlement does not establish worldwide freedom to operate. Separate analysis is required for each country in which the product is manufactured, sold or imported.

What is the commercial exposure from generic entry?

Vimovo revenue exposure depends on the US share of sales, payer substitution, generic pricing and the timing of authorized or independent generic entry. Generic entry can reduce branded net sales rapidly because the active ingredients are chemically substitutable and the product is dispensed through the prescription-drug channel.

The highest-value commercial assets are:

The fixed-dose combination itself.
The delayed-release tablet architecture.
The ulcer-reduction labeling.
Any remaining Orange Book patent term.
Any settlement-controlled launch date.

Once multiple ANDA products enter, price erosion is typically more severe than under a single authorized-generic arrangement. The commercial impact also depends on whether the generic matches both marketed strengths and whether payers require prior authorization for the branded product.

Key Takeaways

US Patent 9,161,920 covers a naproxen/esomeprazole tablet used to reduce NSAID-associated gastric ulcers.
Claim 1 is a broad functional method claim. Claim 11 is a narrower structural claim directed to a naproxen core, pH-dependent coating and gastric-release esomeprazole layer.
The central infringement issues are the dosage ranges, pH 3.5 release threshold, core-layer architecture and stomach release of esomeprazole.
The patent does not cover ordinary use of separate naproxen and esomeprazole products.
Claims directed to carriers, excipients and pH-adjusting ingredients are weaker commercially than the core-release claims.
Vimovo is a small-molecule product. Generic competitors use the ANDA pathway, not the biosimilar pathway.
Orange Book listing, patent-term adjustment, terminal disclaimers and any settlement terms determine current blocking value.
Generic entry may occur after expiration, through a Paragraph IV challenge, through a design-around, or under a license or authorized-generic arrangement.
US coverage does not establish freedom to operate outside the United States.
The patent’s commercial importance is tied to the broader Vimovo patent estate, not to Patent 9,161,920 in isolation.

FAQs

Does Patent 9,161,920 cover Vimovo’s 500 mg/20 mg strength?

Yes, the stated naproxen and esomeprazole ranges encompass a 500 mg naproxen/20 mg esomeprazole tablet, provided the product also satisfies the claimed release and method-of-use limitations.

Can a generic use the same naproxen and esomeprazole doses?

Yes. The active-ingredient doses alone do not determine infringement. The generic must also be assessed for its tablet structure, coating, dissolution profile, labeling and intended use.

Is an enteric-coated esomeprazole layer within the claims?

Claim 11 specifically requires a non-enteric film coating for the esomeprazole layer that releases esomeprazole in the stomach. An esomeprazole design that remains enteric-coated may avoid literal compliance with that limitation, subject to the broader functional language in claim 1.

Does a pH threshold below 3.5 avoid the patent?

It may avoid literal infringement of the express pH 3.5 limitation, but the complete formulation and release behavior must be evaluated. A materially different threshold does not automatically eliminate all infringement theories.

Are separate naproxen and esomeprazole tablets covered?

Generally no, because the claims require a pharmaceutical composition in unit-dose tablet form containing both active ingredients. Separate products may raise other legal or regulatory issues, but they do not ordinarily practice the claimed single-tablet combination.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Code, Title 35, § 154. (2023). Contents and term of patent; provisional rights.
United States Code, Title 21, § 355. (2023). New drugs.
U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,161,920, methods of reducing the incidence of NSAID-associated gastric ulcers.
Amgen Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1411900	⤷ Start Trial	C300481	Netherlands	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	91858	Luxembourg	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	1190013-1	Sweden	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	CA 2012 00036	Denmark	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	2011/016	Ireland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,161,920

Summary for Patent: 9,161,920